Open AccessApatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma
Author(s) -
Mei Jin,
Dawei Zhang,
Qi Zhao,
Wen Zhao,
Cheng Huang,
Xisi Wang,
Chao Duan,
Yan Su,
Xiaoli Ma
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020896
Subject(s) - medicine , apatinib , retinoic acid , isotretinoin , neuroblastoma , adverse effect , malignancy , maintenance therapy , surgery , chemotherapy , tretinoin , oncology , gastroenterology , dermatology , biochemistry , chemistry , genetics , biology , acne , gene , cell culture
Metastatic neuroblastoma (NB) is an aggressive malignancy with a poor prognosis. Many patients present with relapsed high-risk NB after undergoing first-line treatment, and there is no standard therapy available in this setting. Patient concerns: The present study aimed to present the cases of 2 patients with recurrent high-risk NB. Diagnosis: Two children with International Neuroblastoma Stage System stage 4 high-risk NB chemotherapy. The disease recurrent after finishing the treatment. Interventions: Both patients (34 months old and 41 months old) experienced recurrence, received second-line treatment, and then received maintenance treatment using apatinib plus retinoic acid. The apatinib (10 mg/kg per day) and retinoic acid (160 mg/m 2 per day) were administered on alternating 2-week cycles, which was continued for 1 year. Outcomes: The 2 patients had achieved complete response by the 1-year follow-up after starting apatinib plus retinoic acid, and did not experience any adverse drug reactions. Conclusion: The outcomes from these cases suggest that apatinib plus isotretinoin might be an option for maintenance therapy in patients with recurrent high-risk NB.